Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vernonia anthelmintica Willd Injection
- Development stage
- Preclinical
- Lead developer
- The Fifth Affiliated Hospital of Xinjiang Medical University
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
VAWI (Vernonia anthelmintica Willd Injection) is a Xinjiang Uygur medicine being investigated for the treatment of silicosis fibrosis. It is derived from the plant *Vernonia anthelmintica Willd*. Clinical trials are exploring its curative effects and the differences in serum protein expression in patients with silicosis fibrosis.
- Other names
- 驱虫斑鸠菊
02
Targets
VEGFA (Vascular endothelial growth factor A)TYR (Tyrosinase)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)ESR1 (ERα)IL-2 (Interleukin 2)
Beyond the preview
Go deeper on Vernonia anthelmintica Willd Injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vernonia anthelmintica Willd Injection.